Antibiotic susceptibility differs among *Citrobacter* subtypes and treatment has been based on individual antimicrobial profiles. One study of 22 cases of *C. freundii* showed 100% resistance to erythromycin, ampicillin, and methicillin. As was demonstrated in our case study, macrolides including erythromycin and roxithromycin (often indicated for gram positive/negative cocci infections) were ineffective treatments for *C. braakii*, a gram-negative bacillus. While oral amoxicillin and pivoxyl sulbactam were prescribed after incision and drainage (I&D) in our study, the *Citrobacter* isolate was resistant to amoxicillin. Therefore, the I&D procedure was primarily responsible for patient improvement.

To our knowledge, this is the first reported case of *C. braakii*-induced periungual abscess in a patient with chronic paronychia. Additional data on *Citrobacter* infections are needed to improve comprehension of risk factors, etiology, clinical features, and management of these infections.

### REFERENCES

1. Nayar R, Shukla I, Sultan A. Epidemiology, prevalence and identification of *Citrobacter* species in clinical specimens in a tertiary care hospital in India. Int J Sci Res Publ 2014;4:1-6.
2. Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol 2002;47:73-76.
3. Samonis G, Karageorgopoulos DE, Kofteridis DP, Mathaiou DK, Sidiropoulou V, Maraki S, et al. *Citrobacter* infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis 2009;28:61-68.
4. Whalen JG, Mully TW, English JC 3rd. Spontaneous *Citrobacter freundii* infection in an immunocompetent patient. Arch Dermatol 2007;143:124-125.
5. Abo-State MA, Mahdy HM, Ezzat SM, El Shakour EHA, El-Bahnasawy MA. Antimicrobial resistance profiles of Enterobacteriaceae isolated from rosetta branch of river Nile, Egypt. World Appl Sci J 2012;19:1234-1243.

http://dx.doi.org/10.5021/ad.2016.28.4.529

---

A Rare Cutaneous Adverse Reaction after Intra-Articular Injection of Hyaluronic Acid

Hee-Chul Chung, Hana Bak, Jin Wook Lee, Sung Ku Ahn

**Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea**

Dear Editor:

Hyaluronic acid (HA) is a high-molecular-weight polysaccharide found throughout the extracellular matrix and is one of the major components of articular joints. Intra-articular injection of HA is often performed for the treatment of symptomatic osteoarthritis. The efficacy of HA injection in relieving pain and improving function in patients with osteoarthritis has been reported previously. Adverse reactions are usually limited to local reactions at the inoculation site, including transient local tenderness. Although HA has been acknowledged as safe, there have been many reports related to a variety of adverse effects to
injection site is on her scapula of the back area.

A 59-year-old female presented with diffuse skin eruption with pruritus on the left arm and trunk. She had osteoarthritis and intra-articular injection of HA was performed on her left shoulder in order to relieve left shoulder pain 5 days prior. This was the first time for the patient to be injected by HA. There was no relevant contact history and no history of dermatologic disease. Physical examination revealed diffuse edematous erythema, vesicles and bullae with localized erosion on her left arm and trunk (Fig. 1). Blood sampling showed mild leukocytosis (9,890/μl), but all other results were within normal limits. Histopathologically, severe papillary dermal edema and superficial perivenular mixed inflammatory cell infiltrates were observed with an increased number of eosinophils (Fig. 2). The patient was diagnosed with an acute allergic reaction accompanying cellulitis. Within 1 week of short-term systemic corticosteroid and antibiotic therapy, the cutaneous lesions resolved.

Intra-articular HA injection is a universal, safe non-surgical therapy indicated for patients with osteoarthritis. Adverse events following intra-articular injection of HA are unusual. Most reactions are transient, local erythematous responses including pain, tenderness, edema and heat sensation.

There have been some previous reports related to the dermatologic side effects of injectable HA. A 70-year-old female patient manifested a generalized target-like rash with confluent edema after intra-articular HA injection and exhibited a positive reaction on an intradermal test for HA.

She was diagnosed with erythema multiforme due to HA. Another patient, a 68-year-old woman, had a history of knee osteoarthritis and demonstrated knee swelling, painful erythema and bullae with desquamation after intra-articular HA injection. Histologic findings showed subcorneal cleavage, she was positive for exfoliative toxin B and bacterial culture grew methicillin-sensitive Staphylococcus aureus, supporting a diagnosis of staphylococcal scaled skin syndrome. There was also a report describing a delayed granulomatous response after injection of HA used as a soft tissue filler. This patient developed a subepidermal blister with histopathologic features that varied from those above.

HA has no known immunogenic side effects, but it is possible to develop anti-HA antibodies. An allergic reaction can develop resulting in clinically severe erythema, blisters and histopathologic subepidermal cleavage with perivascular lymphocytes and eosinophils in the patient. Unfortunately, the assay for antibodies against HA was not performed in this case. In addition, we did not perform the patch test because of the patient’s refusal and worry about systemic adverse reaction. The lack of these tests could not fully explain the allergic reaction. There is also a possibility of allergic reaction for antiseptic agent such as povidone. The pathomechanism is still unknown although the foreign body or hypersensitivity reaction may be hypothesized. Further elucidation is needed.

We introduce a case of severe cutaneous adverse reaction triggered by HA intra-articular injection; serious side effects of this procedure are rare with only a few reported cases. This report indicates that a relatively common therapeutic procedure with low immunogenicity can trigger severe systemic allergic reactions.
REFERENCES

1. Petrella RJ, Petrella M. A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee. J Rheumatol 2006;33:951-956.

2. Calvo M, Tornero P, De Barrio M, Minquez G, Infante S, Herrero T, et al. Erytema multiforme due to hyaluronic acid (go-on). J Investig Allergol Clin Immunol 2007;17:127-128.

3. Kim JH, Choi JS, Yun JH, Kang HK, Baek JO, Roh JY, et al. Foreign body reaction to injectable hyaluronic acid: late granuloma formation. Ann Dermatol 2015;27:224-225.

4. Kunugiza Y, Tani M, Tomita T, Yoshikawa H. Staphylococcal scalded skin syndrome after intra-articular injection of hyaluronic acid. Mod Rheumatol 2011;21:316-319.

5. Micheels P. Human anti-hyaluronic acid antibodies: is it possible? Dermatol Surg 2001;27:185-191.